{"id":"NCT00828750","sponsor":"GlaxoSmithKline","briefTitle":"Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)","officialTitle":"Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study>","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2011-02","completion":"2011-02","firstPosted":"2009-01-26","resultsPosted":"2011-12-01","lastUpdate":"2018-09-17"},"enrollment":19,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Thrombocytopenic Purpura","Purpura, Thrombocytopenic, Idiopathic"],"interventions":[{"type":"DRUG","name":"Eltrombopag oral tablets","otherNames":["SB-497115-GR oral tablets"]}],"arms":[{"label":"Treatment","type":"EXPERIMENTAL"}],"summary":"An open-label, dose-adjustment extension study to evaluate the safety and efficacy of eltrombopag for treatment of subjects with ITP who have previously been enrolled in the eltrombopag trial TRA108109 (NCT00540423).","primaryOutcome":{"measure":"Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category","timeFrame":"From Baseline (Day 1) to last dose of eltrombopag/early withdrawal visit (up to 981 days)","effectByArm":[{"arm":"Eltrombopag","deltaMin":19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":14},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":["23896965"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":19},"commonTop":["Nasopharyngitis","Headache","Bronchitis","Diarrhoea","Iron deficiency anaemia"]}}